Greece Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$1995
Buy Report Download FREE Resources

Published: September 16, 2022 Report Code: GDHC0055CHR-ST

Select Item

Greece Healthcare Market Overview

The Greek healthcare sector contributes significantly to the country’s economy. It is beginning to become a major player in the medical travel industry due to its temperate climate, highly trained medical staff, and cutting-edge medical facilities. The Greece healthcare market research report gives an overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers. It profiles and provides a SWOT analysis of the major players in the pharmaceutical and medical device market. It also provides insights into its demographic, regulatory and reimbursement landscape, and healthcare infrastructure.

Greece Pharmaceutical Market Analysis

The Greek pharmaceutical market size was $9.4 billion and is expected to grow at a CAGR of more than 4% during 2021 – 2025. The UK, France, Germany, Cyprus, and Japan are major export partners of pharmaceutical products. More than one-fourth of the exports have been to France, followed by Germany, and the UK. Meanwhile, the US, Germany, Italy, the Netherlands, France, the UK, and Luxembourg, are major suppliers of medical equipment to Greece. In the deal scenario, M&A was the preferred deal type in 2020–22.

Greece Pharmaceutical Market Overview

Greece Pharmaceutical Market Overview

For more insights on Greece pharmaceutical market forecast, download a free report sample

Greece Pharmaceutical Market Segments

The key segments of the Greek pharmaceutical market are generic drugs, biologics, biosimilars and over the counter (OTC) medicines. Usage of generic drugs is low in Greece due to widespread distrust. Patients with chronic conditions requiring expensive medications are reluctant to switch over to cheaper generic drugs. ​Furthermore, Greek OTC medicines market is witnessing a steady growth and is forecast to continue doing so in the coming years.

Greece Pharmaceutical Market Analysis by Key Therapy areas

The major therapy areas of the Greek pharmaceutical market are gastrointestinal, cardiovascular, central nervous system, dermatology, and hematological disorders. The pharmaceutical consumption for cardiovascular drugs has increased in the recent years due to the rising incidence of cardiovascular diseases in Greece caused by unhealthy eating habits, depression, and anxiety. ​

Greece Pharmaceutical Market Analysis, by Key Therapy Areas

Greece Pharmaceutical Market Analysis, by Key Therapy Areas

To know more about Greece pharmaceutical market therapeutic areas, download a free report sample

Competitive Landscape

Some of the leading companies in the Greek pharmaceutical market are Pfizer, Sanofi, Novartis, GlaxoSmithKline (GSK), and Lavipharm among others.

Greece Pharmaceutical Market, by Leading Companies

Some of the leading companies in the Greek pharmaceutical market are Pfizer, Sanofi, Novartis, GlaxoSmithKline (GSK), and Lavipharm among others.

To know more about leading companies in the Greece pharmaceutical industry, download a free report sample

Greece Medical Devices Market Analysis

Greece medical devices market value was $1.5 billion in 2021 and is expected to grow at a CAGR of more than 1% during 2022 – 2027. The Greek medical devices market relies heavily on imports. Domestic manufacturing is limited to low-value products such as bandages, gauze, and basic hospital furniture. ​ Key suppliers of medical equipment to Greece are the US, Germany, and Italy, and to a smaller degree the Netherlands, France, the UK, and Luxemburg. Among the deal types, M&A was the preferred deal type in 2020–22.​

Greek Medical Devices Market Overview

Greek Medical Devices Market Overview

For more insights on Greece medical devices market forecast, download a free report sample

Greece Medical Devices Market Segmentation by Key Equipment Sectors

The key equipment sectors in the Greek medical devices market are in vitro diagnostics, drug delivery devices, and neurology devices.

Competitive Landscape

Some of the leading companies in the Greek medical devices market are F. Hoffmann-La Roche Ltd., Fresenius, Abbott, GE Healthcare, and Alcon among others.

Greece Medical Devices Market, by Leading Players

Greece Medical Devices Market, by Leading Players

To know more about leading companies in the Greece medical devices industry, download a free report sample

Greece Healthcare Market Report Overview

Pharmaceutical Market Size (2021) $9.4 Billion
Pharmaceutical CAGR (2021 – 2025) >4%
Pharmaceutical Market Segments Generic Drugs, Biologics, Biosimilars, and Over the Counter (OTC) Medicines
Key Therapy Areas (Pharmaceutical) Gastrointestinal, Cardiovascular, Central Nervous System, Dermatology, and Hematological Disorders
Leading Companies (Pharmaceutical) Pfizer, Sanofi, Novartis, GlaxoSmithKline (GSK), and Lavipharm
Medical Devices Market Size (2021) $1.5 Billion
Medical Devices CAGR (2022 – 2027) >1%
Medical Devices Market Segments Hospital Supplies, Cardiovascular Devices, Wound Care Management, Orthopedic Devices, and Aesthetic Devices
Key Equipment Sectors In Vitro Diagnostics, Drug Delivery Devices, and Neurology Devices
Leading Companies (Medical Devices) F. Hoffmann-La Roche Ltd., Fresenius, Abbott, GE Healthcare, and Alcon

Reasons to Buy

This report will enhance your decision-making capability by allowing you to:

  • Develop business strategies by understanding the trends shaping and driving the Greece healthcare market

  • Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments and companies likely to impact the Greece healthcare market in the future

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing competitors’ performance

  • Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment, and strategic partnership

Table of Contents

1. Table of Contents

1.1 List of Figures

1.2 List of Tables

2. Executive Summary

2.1 Executive Summary

2.2 Key Highlights: Facts About the Greece Healthcare Market

2.3 Key Highlights: Healthcare Startups in Greece

2.4 Key Events: Greece Healthcare Timeline, 2016–22

2.5 Key Events: Greece Pharmaceutical Market

2.6 Key Events: M&As, VC & PE Deals, Global Pharmaceutical Market, 2021–22

2.7 Key Events: Mergers and Acquisitions

2.8 Country Profile, Greece, 2021

3. Overview of Pharmaceutical Market

3.1 Pharmaceutical Market – Overview

3.2 Pharmaceutical Market – Exports

3.3 Pharmaceutical Market – Imports

3.4 Pharmaceutical Market – Supply Channels, Greece

3.5 Pharmaceutical Market – Market Segments

3.6 Pharmaceutical Market – Market Segments, Generics, Greece

3.7 Pharmaceutical Market – Market Segments, Biologics and Biosimilars, Greece

3.8 Pharmaceutical Market – Market Segment, Over-the-Counter Medicines, Greece

3.9 Pharmaceutical Market – Major Therapeutic Areas, Greece

3.10 COVID-19 Epidemiology, Greece

3.11 COVID-19 Impact and Developments in the Healthcare Market, Greece

3.12 COVID-19 Clinical Trials Landscape, Greece

3.13 Pharmaceutical Market – Major Players

4. Overview of Medical Devices Market

4.1 Medical Device Market – Overview

4.2 Medical Devices Market – Major Players

5. Pharmaceutical and Medical Devices Market – Drivers and Barriers

5.1 Drivers

5.2 Barriers

6. Deal Analysis

6.1 Deal Analysis: Pharmaceutical Market, Greece, 2020–22

6.2 Deal Analysis: Medical Device Market, Greece, 2020–22

7. Healthtech Landscape

7.1 Healthtech Landscape, Greece

7.2 Healthtech Deals Landscape, Greece

7.3 Key Healthtech Deals, Greece

7.4 Adoption of Technology in Healthcare, Greece

7.5 Major Digital Regulations, Greece

7.6 Digital Healthcare Regulations, Greece

7.7 Digital Statistics, Greece

7.8 Healthtech Landscape: Benefits and Risks, Greece

8. Market Access

8.1 Overview of Healthcare System, Greece

8.2 Reimbursement Landscape, Greece

8.3 Overview of Insurance Providers, Greece

8.4 Healthcare Spending and Prescription Drug Price Trend, Greece

8.5 Pricing Policies, Greece

8.6 Market Access Timeline, Greece, 2013–22

8.7 Regulatory Landscape, Greece

8.8.1 Marketing Authorization for Pharmaceutical Products, Greece

8.8.2 Marketing Authorization for Biosimilars, Greece

8.8.3 Marketing Authorization for Medical Devices, Greece

8.8.4 Pharmaceutical and Medical Device Establishment Regulations, Greece

8.8.5 Intellectual Property Rights, European Patent, Greece

8.8.6 Intellectual Property Rights, European Unitary Patent, Greece

8.8.7 Intellectual Property Rights, Patents, Greece

8.8.8 Intellectual Property Rights, Trademark, Greece

8.8.9 Clinical Trial Regulation Process, Greece

8.8.10 Pharmaceutical Clinical Trials Landscape, Greece

8.8.11 Pharmaceutical Import and Export, Greece

8.8.12 Pharmaceutical Advertising Regulations, Greece

8.8.13 Pharmaceutical Licensing Regulations, Greece

8.8.14 Labeling and Packaging Regulations, Greece

9. Country Healthcare Landscape

9.1 Healthcare Policy Highlights- Greece

9.2 Healthcare Facilities, Greece

9.3 Life Expectancy and Immunization Rate, Greece

9.4 Environmental Health, Greece

9.5 Healthcare Personnel, Greece

9.6 Disease Burden, Greece

9.7 Healthcare Expenditure, Greece

9.8 Healthcare Spending Components and Pharmaceutical Spending, Greece

10 Trade Associations, Greece

11 Trade Fairs, Greece

12 Opportunities and Challenges

13 Appendix

13.1 Research Methodology

13.1.1 Coverage

13.1.2 Secondary Research

13.1.3 Forecasts

13.2 Bibliography

13.3 About GlobalData

13.4 Contact Us

13.5 Disclaimer

Table

Table 1: Approved biosimilars, EU, 2020–21

Table 2: COVID-19 indicators, global and Greece, 2022

Table 3: Authorized COVID-19 vaccines, Greece, 2020–22

Table 4: Available COVID-19 IVD products, Greece, 2020–22

Table 5: Available COVID-19 IVD products, Greece, 2020–22

Table 6: Medical devices market, major segments ($M), Greece, 2021

Table 7: Overview of healthcare reforms, Greece, 2018-22

Table 8: Time taken from marketing authorization to listing as per therapeutic area, Greece, 2022

Table 9: Drug pricing mechanism, Greece, 2022

Table 10: Drug prices, Greece, 2022

Table 11: New generic drugs price, Greece, 2022

Table 12: New pharmaceutical drugs price, Greece, 2022

Table 13: Trade fairs, Greece, 2022

Figures

Figure 1: Pharmaceutical market, revenue ($B), Greece, 2015–21

Figure 2: Medical devices market, revenue ($B), Greece, 2016–21

Figure 3: Healthcare start-ups in Greece, 2022

Figure 4: Country profile, Greece, 2022

Figure 5: Pharmaceutical market, revenue ($B), Greece, 2015–21

Figure 6: Pharmaceutical market, forecast revenue ($B), Greece, 2022–25

Figure 7: Pharmaceutical exports ($B), Greece, 2013–21

Figure 8: Top export partners, Greece, 2021

Figure 9: Pharmaceutical imports ($B), Greece, 2013–21

Figure 10: Top import partners, Greece, 2021

Figure 11: Framework of the Cross-departmental task force on counterfeit medicines in Greece, 2022

Figure 12: Number of Pharmacies per 100,000 population, Greece, 2019

Figure 13: Number of wholesalers, Greece, 2011–19

Figure 14: Number of pharmacies, Greece, 2011–19

Figure 15: Penetration of pharmaceuticals (volume %), Greece, 2020

Figure 16: Generic drugs average price per unit ($), Greece, 2013–19

Figure 17: OTC medicines market, revenue ($M), Greece, 2013–21

Figure 18: OTC medicines market, major categories ($M), Greece, 2021

Figure 19: OTC medicines market, major distribution channels ($M), Greece, 2021

Figure 20: Pharmaceutical consumption (million packages), Greece, 2011–18

Figure 21: Major therapeutic areas by pharmaceutical consumption (DDD per 1,000 inhabitants per day), Greece, 2019–21

Figure 22: COVID-19 (cumulative number of cases), Greece, 2020–22

Figure 23: COVID-19 (cumulative number of deaths), Greece, 2020–22

Figure 24: COVID-19 stringency index, Greece, 2020–22

Figure 25: COVID-19 containment and health index, Greece, 2020–22

Figure 26: COVID-19 vaccine dose administration (number of administered vaccine doses), Greece, 2021–22

Figure 27: COVID-19 clinical trials sponsors by count, Greece, 2020–22

Figure 28: COVID-19 clinical trials count by phase, Greece, 2020–22

Figure 29: COVID-19 clinical trials count by trial status, Greece, 2020–22

Figure 30: Medical devices market, revenue ($B), Greece 2016–21

Figure 31: Medical devices market, revenue forecast ($B), Greece 2022–27

Figure 32: Medical devices market, major segments (%), Greece, 2021

Figure 33: Hospital supplies market, revenue ($M), Greece, 2017–27

Figure 34: Cardiovascular devices market, revenue ($M), Greece, 2017–27

Figure 35: Wound care management market, revenue ($M), Greece, 2017–27

Figure 36: Orthopedic devices market, revenue ($M), Greece, 2017–27

Figure 37: Aesthetic devices market, revenue ($M), Greece, 2017–27

Figure 38: Diagnostic market, revenue ($M), Greece, 2016–21

Figure 39: Diagnostic market, revenue ($M), Greece, 2022–27

Figure 40: Medical devices market, revenue ($B) of major companies, Greece, 2021

Figure 41: Deals value and deal count, pharmaceutical market, Greece, 2020–22

Figure 42: Top therapy areas by deal count, pharmaceutical market, Greece, 2020–22

Figure 43: Deals value and deal count, subtypes, pharmaceutical market, Greece, 2020–22

Figure 44: Deals value and deal count, medical devices market, Greece, 2020–22

Figure 45: Deals value and deal count, quarterly, medical devices market, Greece, 2020–22

Figure 46: Deals value and deal count, subtypes, medical devices market, Greece, 2020–22

Figure 47: Top equipment sectors by deal value ($M), medical devices market, Greece, 2019–22

Figure 48: Top equipment sectors by deal count, medical devices market, Greece, 2019–22

Figure 49: M&A deals by quarter (by value and by number), medical devices market, Greece, 2019–22

Figure 50: VC deals by quarter (by value and by number), medical devices market, Greece, 2019–22

Figure 51: Deals value ($M), Healthtech, Greece, 2020–22

Figure 52: Deal count (number of deals), Healthtech, Greece, 2020–22

Figure 53: GDPR compliance checklist, EU, 2022

Figure 54: Overview of healthcare system, Greece, 2022, objectives, Taiwan, 2021

Figure 55: Reimbursement process, Greece, 2022

Figure 56: VHI Coverage (% of total population), Greece, 2010–18

Figure 57: OOP expenditure (% of current expenditure on health), Greece, 2013–20

Figure 58: Pharmaceutical price index in healthcare sector (Base year 2015=100), Greece, 2011–19

Figure 59: Drug pricing process, Greece, 2022

Figure 60: Drug authorization procedures, EU, 2022

Figure 61: Centralized procedure, Greece, 2022

Figure 62: Decentralized procedure, Greece, 2019

Figure 63: Mutual recognition procedure, Greece, 2019

Figure 64: Marketing authorization for pharmaceutical products, Greece, 2022

Figure 65: Conformity assessment of class I medical devices, EU, 2022

Figure 66: Conformity assessment of class IIa medical devices, EU, 2022

Figure 67: Conformity assessment of class IIb medical devices, EU, 2022

Figure 68: Conformity assessment of class III medical devices, EU, 2022

Figure 69: European patent approval process, EU, 2022

Figure 70: Unitary patent approval process, EU, 2022

Figure 71: Patent approval process, Greece, 2022

Figure 72: Pharmaceutical clinical trials count by trial status, Greece, 2020–22

Figure 73: Pharmaceutical clinical trials count by phase, Greece, 2020–22

Figure 74: Pharmaceutical clinical trials count by therapy areas, Greece, 2020–22

Figure 75: Top five pharmaceutical clinical trials sponsors by count, Greece, 2020–22

Figure 76: Medical devices clinical trials count by trial status, Greece, 2020–22

Figure 77: Medical devices clinical trials count by indication, Greece, 2020–22

Figure 78: Medical devices clinical trials count by therapeutic areas, Greece, 2020–22

Figure 79: Top five medical devices clinical trials sponsors by count, Greece, 2020–22

Figure 80: Number of hospitals, Greece, 2013–21

Figure 81: Number of diagnostic equipment units (per million population), Greece, 2015–21

Figure 82: Number of hospital beds (per 1,000 Population), Greece, 2013–21

Figure 83: Number of acute care beds (per 1,000 Population), Greece, 2015–21

Figure 84: Number of psychiatric care beds (per 1,000 Population), Greece, 2015–21

Figure 85: Life expectancy at birth (years), Greece, 2013–21

Figure 86: Immunization coverage (%), Greece, 2020

Figure 87: PM2.5 (µg per m3), Greece, 2013–21

Figure 88: CO2 emissions (Mt CO2), Greece, 2013–21

Figure 89: Physicians (per 1,000 population), Greece, 2011–21

Figure 90: Dentists (per 1,000 population), Greece, 2011–21

Figure 91: Nurses (per 1,000 population), Greece, 2012–21

Figure 92: Major causes of mortality (per 100,000 population), Greece, 2019

Figure 93: Major causes of male mortality (per 100,000 population), Greece, 2019

Figure 94: Major causes of female mortality (per 100,000 population), Greece, 2019

Figure 95: DALY (per 100,000 population), Greece, 2019

Figure 96: Healthcare expenditure as percentage of GDP (%), Greece, 2011–20

Figure 97: Public-private share (% of total health spending), Greece, 2011–20

Figure 98: Healthcare expenditure components by function (% of total health expenditure), Greece, 2020

Figure 99: Pharmaceutical spending ($ per capita), Greece, 2010–18

Frequently asked questions

Greece Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape standard reports
Currency USD
$1,995

Can be used by individual purchaser only

Most Popular
$2,992

Can be shared by unlimited users within one corporate location e.g. a regional office

$3,990

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Greece Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Pharmaceuticals reports
Pharmaceuticals
New
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…
$3,495 | June 2026
Pharmaceuticals
New
Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Pharmaceuticals
New
Overweight and Obesity: Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Greece Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape in real time.

  • Access a live Greece Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more